Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

Benzinga Newsdesk www.benzinga.com Positive 93.1%

Neg 0% Neu 0% Pos 93.1%

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.